BR9912707A - Novos compostos - Google Patents

Novos compostos

Info

Publication number
BR9912707A
BR9912707A BR9912707-5A BR9912707A BR9912707A BR 9912707 A BR9912707 A BR 9912707A BR 9912707 A BR9912707 A BR 9912707A BR 9912707 A BR9912707 A BR 9912707A
Authority
BR
Brazil
Prior art keywords
alkyl
cycloalkyl
hydrogen
new compounds
conh
Prior art date
Application number
BR9912707-5A
Other languages
English (en)
Inventor
Steven Coulton
Riccardo Novelli
Roderick Alan Porter
Mervyn Thompson
Robert William Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9912707A publication Critical patent/BR9912707A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

"NOVOS COMPOSTOS". Os compostos da fórmula (I) ou um sal ou solvato dos mesmos, onde: m é 1 ou 2; n é 1 ou 2; X é CH ou N; Y é selecionado de hidrogênio, halogênio, ciano, CF~ 3~, alquila ou alcóxi; R^ 1^ que pode estar em qualquer posição dentro do sistema de anel saturado é hidrogênio ou até dois substitutos que podem ser os mesmos ou diferentes e cada um dos quais é selecionado de flúor ou alquila C~ 1-6~; R^ 2^ é hidrogênio ou até quatro substitutos selecionados de halogênio, NO~ 2~, CN, N~ 3~, CF~ 3~O-, CF~ 3~S-, CF~ 3~CO-, alquila C~ 1-6~, alquenila C~ 1-6~, alquenila C~ 1-6~, alquinila C~ 1-6~, perfluoralquila C~ 1-6~, cicloalquila C~ 3-6~, cicloalquila C~ 3-6~ -alquila C~ 1-4~, alquila C~ 1-6~ O-alquila C~ 1-6~ CO-, cicloalquila C~ 3-6~ O-, cicloalquila C~ 3-6~ CO-, cicloalquila C~ 3-6~alquila C~ 1-4~ O-, cicloalquila C~ 3-6~ -alquila C~ 1-4~ CO-, fenila, fenóxi, benzilóxi, benzoila, fenila-alquila C~ 1-4~, alquila C~ 1-6 S-, alquila C~ 1-6~ SO~ 2~-, (alquila C~ 1-4~) NSO~ 2~-, (alquila C~ 1-4~) NHSO~ 2~- (alquila C~ 1-4~)~ 2~ NCO~ 2~-, oxazolil, (alquila C~ 1-4~) NHCO-, CONH~ 2~; ou R^ 4^CONH- ou -NR^ 4^R^ 5^, onde R^ 4^ é hidrogênio ou alquila C~ 1-4~, e R~ 5~ é hidrogênio, alquila C~ 1-4~, formila, -CO~ 2~ alquila C~ 1-4~, ou -CO alquila C~ 1-4~, ou dois grupos R~ 2~ são ligados formando um anel carbocíclico ou heterocíclico que é saturado ou insaturado e substituído ou não por -OH ou = O são indicados como sendo úteis no tratamento e profilaxia de epilepsia, enxaqueca e outros distúrbios.
BR9912707-5A 1998-08-05 1999-08-03 Novos compostos BR9912707A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9817028.5A GB9817028D0 (en) 1998-08-05 1998-08-05 Novel compounds
PCT/EP1999/005584 WO2000008020A2 (en) 1998-08-05 1999-08-03 Tricyclic carboxamides

Publications (1)

Publication Number Publication Date
BR9912707A true BR9912707A (pt) 2001-11-06

Family

ID=10836742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912707-5A BR9912707A (pt) 1998-08-05 1999-08-03 Novos compostos

Country Status (26)

Country Link
EP (1) EP1102769B1 (pt)
JP (1) JP2002522436A (pt)
KR (1) KR20010072262A (pt)
CN (1) CN1324359A (pt)
AR (1) AR020002A1 (pt)
AT (1) ATE237615T1 (pt)
AU (1) AU754638B2 (pt)
BR (1) BR9912707A (pt)
CA (1) CA2339362A1 (pt)
CO (1) CO5080783A1 (pt)
CZ (1) CZ293667B6 (pt)
DE (1) DE69906985T2 (pt)
DK (1) DK1102769T3 (pt)
ES (1) ES2197665T3 (pt)
GB (1) GB9817028D0 (pt)
HK (1) HK1037919A1 (pt)
HU (1) HUP0103311A3 (pt)
IL (1) IL141164A0 (pt)
NO (1) NO20010584L (pt)
NZ (1) NZ509685A (pt)
PL (1) PL346167A1 (pt)
PT (1) PT1102769E (pt)
TR (1) TR200100364T2 (pt)
TW (1) TW518334B (pt)
WO (1) WO2000008020A2 (pt)
ZA (1) ZA200100902B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013318182C1 (en) 2012-09-18 2022-01-20 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX369956B (es) 2013-12-03 2019-11-27 Auspex Pharmaceuticals Inc Metodos para preparar compuestos de benzoquinolina.
IL305352A (en) 2015-03-06 2023-10-01 Auspex Pharmaceuticals Inc Methods for treating abnormal movement disorders
CN108912118A (zh) * 2018-07-12 2018-11-30 新乡学院 一种四氢异喹啉并三嗪骨架化合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0067565A1 (en) * 1981-06-16 1982-12-22 Beecham Group Plc Pharmaceutically active compounds

Also Published As

Publication number Publication date
ATE237615T1 (de) 2003-05-15
TR200100364T2 (tr) 2001-09-21
AR020002A1 (es) 2002-03-27
PT1102769E (pt) 2003-08-29
IL141164A0 (en) 2002-11-10
PL346167A1 (en) 2002-01-28
CA2339362A1 (en) 2000-02-17
JP2002522436A (ja) 2002-07-23
TW518334B (en) 2003-01-21
EP1102769B1 (en) 2003-04-16
NO20010584D0 (no) 2001-02-02
CZ293667B6 (cs) 2004-06-16
AU5509899A (en) 2000-02-28
DK1102769T3 (da) 2003-08-11
ES2197665T3 (es) 2004-01-01
GB9817028D0 (en) 1998-09-30
NZ509685A (en) 2003-07-25
WO2000008020A8 (en) 2001-04-26
AU754638B2 (en) 2002-11-21
DE69906985D1 (en) 2003-05-22
EP1102769A2 (en) 2001-05-30
HUP0103311A2 (hu) 2002-02-28
KR20010072262A (ko) 2001-07-31
HK1037919A1 (en) 2002-02-22
DE69906985T2 (de) 2004-02-12
CZ2001436A3 (cs) 2001-08-15
WO2000008020A2 (en) 2000-02-17
WO2000008020A3 (en) 2000-07-13
CO5080783A1 (es) 2001-09-25
NO20010584L (no) 2001-02-02
HUP0103311A3 (en) 2002-10-28
ZA200100902B (en) 2002-05-14
CN1324359A (zh) 2001-11-28

Similar Documents

Publication Publication Date Title
DE69524641D1 (de) Benzamidanaloga zur Verwendung als PARP- (ADP-Ribosyltransferase, ADPRT) DNS-Reparaturenzym Inhibitoren
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
BR0213455A (pt) Composto, seu uso, composição farmacêutica, método para o tratamento ou prevenção de uma doença para a qual um receptor adenosina está relacionado, e método para promover a defecação
BR9608048A (pt) Compostos de benzimidazol, composições farmacêuticas contendo os compostos e seu uso.
BR9809147A (pt) Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis
MXPA03001072A (es) El uso de bencilidenaminoguanidinas e hidroxiguanidinas como ligandos de receptor de melanocortina.
BRPI0515412A (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
ME00584A (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
BR0010951A (pt) Agente de tixotropização
AR021087A1 (es) Pirimidin-4-iliden-alquilamina 2,3-sustituida 5,6-anillada, composicion para controlar y prevenir plagas, uso de dichos compuestos para proteger a lasplantas contra la infestacion por microorganismos fitopatogenicos, metodo para controlar o prevenir la infestacion de plantas cultivadas por microorga
BR0317705A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças ou condições, e, processo para a preparação de compostos
BR0108512A (pt) Misturas estabilizantes para poliolefinas
BRPI0510078A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição, distúrbios ou doença tratável com androgênios, de tratamento de uma condição, distúrbio ou doença relacionada com receptor de androgênio e de contracepção masculina
BR0017036A (pt) Mistura estabilizadora
BR9912707A (pt) Novos compostos
BR0311315A (pt) Sulfonas aromáticas e sua utilização médica
BR0211171A (pt) Compostos quìmicos
BR0208756A (pt) Compostos, processo para a preparação dos mesmos, composição adequada para o controle de fungos fitopatogênicos, e, método para controlar fungos fitopatogênicos
BR9913183A (pt) Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica
BR0015401A (pt) [(indol-3-il)-cicloalquil]-3-azetidinas substituìdas para o tratamento de distúrbios do sistema nervoso central
BRPI0414241A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f em um mamìfero, para inibir o extravasamento de proteìna neuronal em um mamìfero e para tratar ou prevenir enxaqueca em um mamìfero, e, uso de um composto
BR9815017A (pt) Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada
BR0111555A (pt) Piridin-2-ilaminoalquilcarbonilglicil-beta-alanina e derivados
BR112017015903A2 (pt) artigos com composição controladora de odor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.